• MDB Direct
  • Community Portal
  • Submit Your Big Idea
MDB Capital
  • Why Public Venture?
    • What is Public Venture?
    • Public Venture Advantage
    • How to Invest
    • MDB Outcomes
  • Why MDB?
    • MDB Difference
    • Investment Criteria
    • Curation Process
    • Outcomes
    • Launch Capabilities
    • MDB Capital Brokerage
    • Community
      • Membership Group
      • Member Criteria & Benefits
  • MDB Direct
    • Overview
    • MDB Direct
    • IRAs
    • Open an Account
  • Media
    • Videos
    • Press Releases
    • Articles
    • Reports
  • About
    • Overview
    • Our Platform
    • Value Creation
    • Join Us
    • Contact
    • Leadership Team
    • Submit Big Idea
  • MDBH Investors
    • Overview
    • Press Releases
    • SEC Filings
    • Stock Info
    • Governance
    • Email Alerts
    • IR Contact
    • Events
Select Page

New PatentVest Pulse Report Reveals Transformative Trends in the AI Data Center Patent Race

by MDB Manager | Mar 5, 2025 | Press Releases

China accounts for 77% of all AI data center patent filings globally, with five of the top patent holders hailing from China – underlining its dominant position in next-generation AI infrastructure Dallas, TX, March 05, 2025 (GLOBE NEWSWIRE) — Today,...

eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering

by MDB Manager | Feb 19, 2025 | Press Releases

Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) — eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen...

Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

by MDB Manager | Feb 12, 2025 | Press Releases

Rebranding Invizyne Technologies, Inc to eXoZymes Inc. Changing NASDAQ ticker from IZTC to EXOZ Introducing but not trademarking “exozymes” as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) — Today, Invizyne Technologies, Inc....

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

by Staff | Feb 10, 2025 | Press Releases

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025. Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) (“Invizyne”), a leading designer of cell-free, enzyme-based biomanufacturing...

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

by Staff | Jan 29, 2025 | Press Releases

SANTA CLARA, Calif.–(BUSINESS WIRE)– HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and...

HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

by Staff | Dec 16, 2024 | Press Releases

First cable-free, ambulatory ECG that captures the heart’s electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG...
« Older Entries
Next Entries »

Recent Posts

  • MDB Capital Holdings Provides First Quarter 2025 Update
  • New PatentVest Pulse Report Reveals IP Gaps in Billion-Dollar Humanoid Robotics Startups
  • MDB Capital Holdings to Host First Quarter 2025 Results Conference Call on Wednesday May 21, 2025, at 4:30 p.m. Eastern Time
  • New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market
  • MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update

Recent Comments

    Archives

    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • July 2024
    • May 2024
    • April 2024
    • February 2024
    • January 2024
    • November 2023
    • October 2023
    • June 2023
    • May 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022

    Categories

    • Press Releases
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Join Mailing List

    Terms of Use  |  Governance  |  Business Continuity  |  Member FINRA/SIPC  |  FINRA’s BrokerCheck  |  Disclosures
    © 2025 MDB Capital